AxioMx offers custom antibody discovery and development services for the research, diagnostic and therapeutic markets. The company is developing a novel, high-throughput method to synthetically generate affinity reagents—fragments of monoclonal antibodies—that bind specific target proteins. Its antibodies are generated entirely in vitro, enabling consistent quality across production batches and avoiding the use of animals. AxioMx reports customers ordered over $750k of custom services in the past nine months, covering antigen design, antibody discovery and affinity maturation. The company was founded in 2012 by Christopher McLeod and Dr. Michael Weiner and is based in Branford, Connecticut. It recently completed a $2M second financing round to support its operations and technology development. AxioMx is an early-stage biotechnology company developing a novel approach to synthetically generate affinity reagents—fragments of monoclonal antibodies that specifically bind target proteins. These reagents are intended for use in life-science research, diagnostic tests and as therapeutics. The company’s technology aims to shorten production time from 4–6 months using traditional methods to under four weeks. AxioMx was launched in 2012 and is led by CEO Christopher McLeod, CSO Michael Weiner, Ph.D., and Tom Thompson, vice president of sales and marketing. It is based in Branford, Connecticut. As of December 2012 the company had secured $2.5M in funding from investors including Connecticut Innovations, Elm Street Ventures and company founders.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2013